New combo therapy could shrink rare lung tumors
NCT ID NCT07357623
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding chemotherapy to surufatinib works better than surufatinib alone for people with a rare lung cancer called pulmonary neuroendocrine tumor. About 96 adults will be randomly assigned to one of two treatment groups. The goal is to see if the combination shrinks tumors more and helps people live longer, while checking for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100000, China
-
Shanghai chest hospital
RECRUITINGShanghai, Shanghai Municipality, 200000, China
-
The First Affiliated Hospital Of Anhui Medical University
NOT_YET_RECRUITINGHefei, Anhui, 230000, China
-
The First Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITINGZhengzhou, Henan, 450000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.